CN101132812A - Hiv进入抑制剂的聚合物基组合物和结合物 - Google Patents

Hiv进入抑制剂的聚合物基组合物和结合物 Download PDF

Info

Publication number
CN101132812A
CN101132812A CNA2005800082104A CN200580008210A CN101132812A CN 101132812 A CN101132812 A CN 101132812A CN A2005800082104 A CNA2005800082104 A CN A2005800082104A CN 200580008210 A CN200580008210 A CN 200580008210A CN 101132812 A CN101132812 A CN 101132812A
Authority
CN
China
Prior art keywords
conjugate
polymer
peg
hydrogel
conjugates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2005800082104A
Other languages
English (en)
Chinese (zh)
Inventor
迈克尔·D·本特利
赵宣
哈罗德·察佩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics AL Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics AL Corp filed Critical Nektar Therapeutics AL Corp
Publication of CN101132812A publication Critical patent/CN101132812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/12—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from polycarboxylic acids and polyhydroxy compounds
    • C08G63/46—Polyesters chemically modified by esterification
    • C08G63/48—Polyesters chemically modified by esterification by unsaturated higher fatty oils or their acids; by resin acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CNA2005800082104A 2004-03-15 2005-03-15 Hiv进入抑制剂的聚合物基组合物和结合物 Pending CN101132812A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55314604P 2004-03-15 2004-03-15
US60/553,146 2004-03-15

Publications (1)

Publication Number Publication Date
CN101132812A true CN101132812A (zh) 2008-02-27

Family

ID=34994420

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2005800082104A Pending CN101132812A (zh) 2004-03-15 2005-03-15 Hiv进入抑制剂的聚合物基组合物和结合物

Country Status (9)

Country Link
US (1) US9446139B2 (enExample)
EP (1) EP1725262B1 (enExample)
JP (1) JP4805911B2 (enExample)
KR (1) KR101276422B1 (enExample)
CN (1) CN101132812A (enExample)
AU (1) AU2005222641B2 (enExample)
CA (1) CA2558583C (enExample)
MX (1) MXPA06010505A (enExample)
WO (1) WO2005089805A2 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法
CN104303058A (zh) * 2012-04-18 2015-01-21 西门子医疗保健诊断公司 用于制备缀合物试剂的化合物和方法

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE444984T1 (de) * 2002-12-31 2009-10-15 Nektar Therapeutics Al Corp Hydrolysestabile maleimidendgruppen-enthaltende polymere
US7432331B2 (en) * 2002-12-31 2008-10-07 Nektar Therapeutics Al, Corporation Hydrolytically stable maleimide-terminated polymers
EP1708734A4 (en) * 2004-01-07 2009-06-17 Trimeris Inc PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS
DE102004031258A1 (de) * 2004-06-29 2006-02-09 Jennissen, Herbert P., Prof. Dr. Proteinhybride mit polyhydroxyaromatischen Aminosäure-Epitopen
EP1885403B1 (en) * 2005-04-12 2013-05-08 Nektar Therapeutics Poly(ethyleneglycol) conjugates of Lysostaphin
PT1989220E (pt) * 2006-02-02 2012-03-23 Trimeris Inc Péptidos inibidores de fusão de hiv com propriedades biológicas melhoradas
US7671067B2 (en) * 2006-02-09 2010-03-02 Enzon Pharmaceuticals, Inc. Treatment of non-hodgkin's lymphomas with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamtothecin
US7462627B2 (en) * 2006-02-09 2008-12-09 Enzon Pharmaceuticals, Inc. Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers
MX2008010841A (es) 2006-02-21 2008-10-27 Nektar Therapeutics Al Corp Polimeros degradables segmentados y conjugados hechos de los mismos.
US20090285780A1 (en) * 2006-05-24 2009-11-19 Chyi Lee Peg linker compounds and biologically active conjugates thereof
EP2054074B8 (en) 2006-08-04 2014-11-12 Prolong Pharmaceuticals, LLC Modified erythropoietin
BRPI0807232A2 (pt) * 2007-02-09 2014-04-29 Enzon Pharmaceuticals Inc Tratamento de cânceres resistentes ou refratários com conjugados poliméricos multi-braços de 7-etil-10-hidroxicamptotecina
EP2134181A4 (en) * 2007-02-28 2011-09-28 Serina Therapeutics Inc ACTIVATED POLYOXAZOLINES AND COMPOSITION COMPRISING THE SAME
US20140011964A1 (en) 2007-02-28 2014-01-09 Serina Therapeutics, Inc. Activated Polyoxazolines and Conjugates and Compositions Comprising the Same
CA2682848A1 (en) * 2007-04-03 2008-10-16 Trimeris, Inc. Novel formulations for delivery of antiviral peptide therapeutics
BRPI0817697A2 (pt) * 2007-09-25 2015-04-07 Trimeris Inc Método de síntese de um peptídeo, conjunto de fragmentos de peptídeo, e, peptídeo
TW201010732A (en) * 2008-08-29 2010-03-16 Enzon Pharmaceuticals Inc Method of treating RAS associated cancer
CN102215688A (zh) * 2008-10-21 2011-10-12 安龙制药公司 用7-乙基-10-羟基喜树碱的多臂聚合物对神经母细胞瘤的治疗
HUE043689T2 (hu) * 2009-11-18 2019-09-30 Nektar Therapeutics Polimer-gyógyszer savas sói
WO2011084458A2 (en) * 2009-12-15 2011-07-14 The Johns Hopkins University Polymer-based compositions and methods for treatment of peritoneal disorders
US20110295365A1 (en) * 2010-05-28 2011-12-01 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Anti-viral compositions and methods for administration

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992013947A1 (en) 1991-02-08 1992-08-20 Progenics Pharmaceuticals, Inc. CD4-GAMMA2 AND CD4-IgG2 CHIMERAS
US5446090A (en) * 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) * 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US5792462A (en) * 1995-05-23 1998-08-11 University Of North Carolina At Chapel Hill Alphavirus RNA replicon systems
EP1411075B1 (en) * 1998-03-12 2008-07-02 Nektar Therapeutics Al, Corporation Method for preparing polymer conjugates
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US20040228869A1 (en) 1998-12-16 2004-11-18 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compositions and antibodies thereto
US6469136B1 (en) 1999-07-07 2002-10-22 Trimeris, Inc. Methods and composition for peptide synthesis
US6541020B1 (en) 1999-07-09 2003-04-01 Trimeris, Inc. Methods and compositions for administration of therapeutic reagents
US6413507B1 (en) * 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
AU2001238595A1 (en) 2000-02-22 2001-09-03 Shearwater Corporation N-maleimidyl polymer derivatives
WO2001064710A2 (en) 2000-02-29 2001-09-07 Progenics Pharmaceuticals, Inc. Sulfated ccr5 peptides for hiv-1 infection
CN100352837C (zh) * 2002-07-24 2007-12-05 弗·哈夫曼-拉罗切有限公司 聚乙二醇化的t1249多肽
DE60335111D1 (de) * 2002-07-24 2011-01-05 Hoffmann La Roche Pegyliertes t20-polypeptid
AU2003258518B2 (en) 2002-07-24 2007-01-18 F. Hoffmann-La Roche Ag Polyalkylene glycol acid additives
EP1546235B1 (en) * 2002-09-09 2021-10-20 Nektar Therapeutics Water-soluble polymer alkanals
US7556813B2 (en) 2002-09-27 2009-07-07 Trimeris, Inc. Antiviral peptide-polymer conjugate comprising a polymer covalently attached to two or more synthetic HIV gp41 HR1 and/or HR2 peptides
CA2508015C (en) 2002-12-30 2012-04-03 Nektar Therapeutics Al, Corporation Multi-arm polypeptide-poly(ethylene glycol) block copolymers as drug delivery vehicles
AU2003300140A1 (en) * 2002-12-31 2004-07-29 Nektar Therapeutics Al, Corporation Methods for the formation of hydrogels using thiosulfonate compositions and uses thereof
AU2003300139B2 (en) * 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
DE602004029646D1 (en) * 2003-01-06 2010-12-02 Nektar Therapeutics San Carlos Thiolselektive wasserlösliche polymerderivate
SI1596887T1 (sl) * 2003-02-26 2022-05-31 Nektar Therapeutics Konjugati polimer-del faktorja VIII
KR101128320B1 (ko) 2003-05-23 2012-04-12 넥타르 테라퓨틱스 아미도카르보네이트 연결기를 갖는 ｐｅｇ 유도체
EP1734994A1 (en) 2004-03-15 2006-12-27 Trimeris, Inc. Site-specific chemical modification of hiv gp41-derived peptides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104303058A (zh) * 2012-04-18 2015-01-21 西门子医疗保健诊断公司 用于制备缀合物试剂的化合物和方法
CN104109240A (zh) * 2014-07-13 2014-10-22 成都市绿科华通科技有限公司 一种可作为药物载体的多孔聚乙二醇的制备方法

Also Published As

Publication number Publication date
US20050226843A1 (en) 2005-10-13
US9446139B2 (en) 2016-09-20
AU2005222641A1 (en) 2005-09-29
JP4805911B2 (ja) 2011-11-02
KR20060130225A (ko) 2006-12-18
MXPA06010505A (es) 2006-12-19
CA2558583A1 (en) 2005-09-29
WO2005089805A3 (en) 2007-07-19
EP1725262B1 (en) 2021-05-26
JP2007529539A (ja) 2007-10-25
KR101276422B1 (ko) 2013-06-19
EP1725262A2 (en) 2006-11-29
WO2005089805A2 (en) 2005-09-29
AU2005222641B2 (en) 2011-04-07
CA2558583C (en) 2013-07-09

Similar Documents

Publication Publication Date Title
JP4805911B2 (ja) Ｈｉｖ侵入阻害剤のポリマー系組成物及び複合体
EP1885403B1 (en) Poly(ethyleneglycol) conjugates of Lysostaphin
JP6728055B2 (ja) Ｉｌ−１５部分とポリマーとのコンジュゲート
JP5431874B2 (ja) ポリエチレングリコール−ｇｒｆ結合体の部位特異的調製方法
CA2978330C (en) Conjugates of an il-7 moiety and a polymer
AU2020202673A1 (en) Conjugates of an IL-2 moiety and a polymer
CN104906594B (zh) 用于与蛋白质和肽缀合的四个支链的树枝状大分子peg
CN1997661A (zh) 抗原性减弱的聚合物缀合物,其制备方法和应用
WO2013020079A2 (en) Conjugates of an il-11 moiety and a polymer
AU2009246851A1 (en) Conjugates of a cholinesterase moiety and a polymer
CA2648582C (en) Conjugates of an anti-tnf-alpha antibody
US20230272001A1 (en) Novel processes for preparing conjugates of the il-2 protein
JP2019532019A (ja) オキシム含有リンケージを有する第ｖｉｉｉ因子部分のコンジュゲート

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
COR Change of bibliographic data

Free format text: CORRECT: ADDRESS; FROM: ALABAMA STATE,USA TO: CALIFORNIA STATE, U.S.A.

TA01 Transfer of patent application right

Effective date of registration: 20100407

Address after: American California

Applicant after: Nektar Therapeutics

Address before: alabama

Applicant before: Nektar Therapeutics Al Corp.

C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20080227